Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab in AL Amyloidosis Patients Not in VGPR or Better
NCT02816476Phase 2Completed
- Sponsor
- CHU de Limoges
- Start
- Sep 2016
- Primary completion
- Oct 2019
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of daratumumab in light-chain amyloidosis, sponsored by CHU de Limoges. Started Sep 2016; status: completed.
02
Drugs
daratumumab
03
Conditions
light-chain amyloidosis
Beyond the preview
Go deeper on NCT02816476.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02816476.